Table 2.
Inverse-variance weighted two-sample Mendelian randomization estimates for antihypertensive drug effects and systolic blood pressure reduction through any mechanism (scaled to 10 mmHg) on the set of outcomes
| Exposure/drug target | Outcome | ORa | LCI 95% | UCI 95% | P-value |
|---|---|---|---|---|---|
| Beta-blocker mediated 10 mmHg SBP reduction (# SNPs = 2) | Pre-eclampsia or eclampsia | 0.27 | 0.06 | 1.19 | 0.08 |
| Gestational diabetes | 2.01 | 0.91 | 4.42 | 0.08 | |
| Birthweighta | − 0.27 | − 0.39 | − 0.15 | 1.90 × 10−05 | |
| Calcium channel blocker mediated 10 mmHg SBP reduction (# SNPs = 23) | Pre-eclampsia or eclampsia | 0.62 | 0.43 | 0.89 | 9.33 × 10−3 |
| Gestational diabetes | 1.05 | 0.76 | 1.45 | 0.76 | |
| Birthweighta | 0.02 | − 0.04 | 0.07 | 0.54 | |
| Systolic blood pressure, any mechanism (10 mmHg reduction, # SNPs = 1336–1346) | Pre-eclampsia or eclampsia | 0.57 | 0.53 | 0.60 | 1.11 × 10−84 |
| Gestational diabetes | 0.94 | 0.90 | 0.99 | 0.01 | |
| Birthweighta | 0.10 | 0.09 | 0.11 | 9.54 × 10−80 |
Abbreviations: OR Odds ratio, LCI Lower bound for 95% confidence interval, UCI Upper bound for 95% confidence interval
abeta coefficient reported for birthweight